Femlyv Kit
Product Images NDC 72495-601

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Femlyv (NDC 72495-601). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Millicent Us, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A horizontal bar chart comparing the number of women with blood clots per 10,000 women years across four groups: Non-Pregnant Non-COC (1 to 5), COC-User (3 to 9), Pregnancy (5 to 20), and Postpartum (12 weeks only) with the highest range from 40 to 65. The chart visually represents ranges of blood clot incidence for each group.*

FDA Label Image

Figure 2 (Image 02)

A forest plot chart titled 'Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives.' It compares effect estimates (Odds Ratios, Relative Risks, and Hazard Ratios) from different studies on breast cancer risk in ever versus never combined oral contraceptive (COC) users and current versus never users. The horizontal axis shows effect estimates ranging from about -1.50 to +2.00, with vertical reference line at 1.00. Individual study results are indicated by points and confidence intervals for each listed study.*

FDA Label Image

Norethindrone Acetate Structural Formula (Image 03)

Chemical structure diagram showing the molecular arrangement of Norethindrone Acetate, featuring numbered carbon atoms and functional groups including a ketone and an acetate ester.*

FDA Label Image

Ethinyl Estradiol Structural Formula (Image 04)

Chemical structure diagram of Norethindrone Acetate/Ethinyl Estradiol, showing the steroid backbone with labeled carbon positions and hydroxyl groups, consistent with the active ingredients of FEMLYV.*

FDA Label Image

Figure 3 (Image 05)

A pharmacokinetic curve showing norethindrone concentration (pg/mL) over time (hours) up to 36 hours. The graph depicts peak concentration at early time points, followed by a gradual decline with error bars indicating variability at each measurement.*

FDA Label Image

Figure 4 (Image 06)

A line graph depicting Ethinyl estradiol concentration (pg/mL) over time in hours, showing a peak concentration shortly after administration followed by a gradual decline over a 36-hour period, with error bars representing variability at each time point.*

FDA Label Image

Chart (Image 07)

A diagram displaying birth control methods categorized by their effectiveness, showing fewer pregnancies at the top and more pregnancies at the bottom. Methods listed from most to least effective include implants, injections, intrauterine devices, sterilization, birth control pills, transdermal patch, vaginal inserts with hormones, condoms, diaphragm, abstinence during fertile days, spermicide, withdrawal, and no birth control at the bottom.*

FDA Label Image

Femlyv Tablet Pack (Image 08)

Pack insert label for FEMLYV kit containing norethindrone acetate and ethinyl estradiol oral disintegrating tablets. The label shows a 28-day calendar dosing guide divided into four weeks with pills arranged left to right by day and week, including instructions for Sunday and Day-1 starters. The strength indicated is 1 mg/0.02 mg, with storage instructions and safety warnings visible. Labeler is Millicent US, Inc.*

FDA Label Image

Femlyv (norethindrone Acetate And Ethinyl Estradiol Orally Disintegrating Tablets) 1mg/0.02mg Carton Label (Image 09)

Packaging label for FEMLYV 1 mg/0.02 mg orally disintegrating tablets kit containing norethindrone acetate and ethinyl estradiol. The 28-day regimen kit includes blisters providing 24 days of active therapy. The label shows the Millicent Pharma logo and states the product is manufactured by Patheon Inc. and distributed by Millicent US, Inc.*

FDA Label Image

Femlyv (norethindrone Acetate And Ethinyl Estradiol Orally Disintegrating Tablets) 1mg/0.02mg Pouch Label (Image 10)

Label for FEMLYV (norethindrone acetate and ethinyl estradiol) orally disintegrating tablets, 1 mg/0.02 mg, in a 28-day regimen kit. The label states each blister provides 24 days of active therapy with 28 orally disintegrating tablets. Distributed by Millicent US Inc., with storage and usage instructions included.*

FDA Label Image

Femlyv (norethindrone Acetate And Ethinyl Estradiol Orally Disintegrating Tablets) 1mg/0.02mg Blister Card Label (Image 11)

FEMLYV kit packaging label showing a blister card of orally disintegrating tablets containing norethindrone acetate and ethinyl estradiol. The card displays a weekly dosing schedule with days of the week indicated in circles, storage instructions, and notes that the product is prescription only. Labeler information is Millicent US, Inc., and the dosage strength is 1 mg/0.02 mg.*

FDA Label Image

Femlyv (norethindrone Acetate And Ethinyl Estradiol Orally Disintegrating Tablets) 1mg/0.02mg Physician's Sample Carton Label (Image 12)

FEMLYV kit containing norethindrone acetate and ethinyl estradiol orally disintegrating tablets, 1mg/0.02mg strength. The packaging indicates a 28-day regimen kit with 24 days of active therapy. The labeler is Millicent US, Inc., and the carton includes physician sample and storage instructions, along with manufacturer details.*

FDA Label Image

Femlyv (norethindrone Acetate And Ethinyl Estradiol Orally Disintegrating Tablets) 1mg/0.02mg Physician's Sample Pouch Label (Image 13)

Label for FEMLYV (norethindrone acetate and ethinyl estradiol) orally disintegrating tablets, 1 mg/0.02 mg. The kit contains a 28-day regimen blister card with 28 orally disintegrating tablets (ODTs). Label states Rx only, physician's sample not for sale, and includes storage instructions and adverse reaction reporting information. Distributed by Millicent US, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.